HK Stock Market Move | ASMPT (00522) rises over 6% again as second-quarter performance and third-quarter guidance both far exceed expectations; order shipment ratio remains at a five-year high.
ASMPT (00522) has risen over 6%, with a cumulative increase of more than 20% this month. As of the time of reporting, it rose 6.55% to HKD 180.6, with a trading volume of HKD 187 million.
ASMPT (00522) rose over 6% again, with a cumulative increase of more than 20% this month. As of the time of writing, it is up 6.55%, priced at HKD 180.6, with a transaction volume of HKD 187 million.
On the news front, ASMPT recently announced its second-quarter results. Adjusted net profit reached HKD 638 million, exceeding market expectations by 76%; revenue was HKD 4.94 billion, 10.5% higher than the midpoint of the companys guidance; and the adjusted gross margin was 42.5%, surpassing market expectations by 2.8 percentage points. During the period, orders amounted to HKD 7.08 billion, with an order-to-shipment ratio of 1.43 times, marking a five-year high. Management anticipates a high single-digit growth in orders for the third quarter compared to the prior quarter, primarily driven by thermocompression bonding and optical communications businesses.
Citi issued a report stating that ASMPT's second-quarter results and third-quarter guidance significantly exceeded expectations, with the order-to-shipment ratio maintaining a five-year high. The recent 35% stock price correction has made the risk-return profile attractive. EB SECURITIES noted that strong demand for AI is driving continuous surges in orders across various fields including TCB, CPO, and FC. The Q2 results for 2026 exceeded market expectations, further validating its global leadership position in the AP field. The companys resources will be further focused on back-end packaging and SMT core businesses, with the profit margin center expected to continue moving upwards.
Related Articles

HK Stock Market Move | SAMSONITE (01910) rose over 7% in early trading as the company plans to spend $178 million to acquire an 85% stake in the parent company of BIS.

HK Stock Market Move | CF PHARMTECH (02652) rose by over 5% after completing the placement of 21.7477 million new H shares. ICF001 is expected to fill the clinical gap in the treatment of PH-ILD.
.png)
Tan Wenkang joins the board of IMAGI INT'L (00585), leveraging his experience in cutting-edge technology and capital markets to support the company's development.
HK Stock Market Move | SAMSONITE (01910) rose over 7% in early trading as the company plans to spend $178 million to acquire an 85% stake in the parent company of BIS.

HK Stock Market Move | CF PHARMTECH (02652) rose by over 5% after completing the placement of 21.7477 million new H shares. ICF001 is expected to fill the clinical gap in the treatment of PH-ILD.

Tan Wenkang joins the board of IMAGI INT'L (00585), leveraging his experience in cutting-edge technology and capital markets to support the company's development.
.png)
RECOMMEND





